Ascendis Pharma-JPM-20240108 .pdf

1、Ascendis Pharma A/S42ndAnnual J.P.Morgan Healthcare ConferenceJanuary 8,2024For investor communication only.Not for use in product promotion.Not for further distribution.Cautionary Note on Forward-Looking StatementsThis presentation contains forward-looking statements.All statements other than state

2、ments of historical facts contained in this presentation,such as statements regarding our products and prospective product candidates;clinical trial results;the expected timing of future clinical trial results and feedback from regulatory authorities;the scope,progress,results and costs of developin

3、g our product candidates or any other future product candidates;timing and likelihood of success;plans and objectives of management for future operations and commercialization activities;and future results of current and anticipated products and product candidates are forward-looking statements.Thes

4、e forward-looking statements are based on our current expectations and beliefs,as well as assumptions concerning future events.These statements involve known and unknown risks,uncertainties and other factors that could cause our actual results to differ materially from the results discussed in the f

5、orward-looking statements.These risks,uncertainties and other factors are more fully described in our reports filed with or submitted to the Securities and Exchange Commission(SEC),including,without limitation,our most recent Annual Report on Form 20-F filed with the SEC on February 16,2023 particul

6、arly in the sections titled“Risk Factors”and“Operating and Financial Review and Prospects.”In light of the significant uncertainties in our forward-looking statements,you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other